These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 28285326)

  • 1. Endogenous opioid system: a promising target for future smoking cessation medications.
    Norman H; D'Souza MS
    Psychopharmacology (Berl); 2017 May; 234(9-10):1371-1394. PubMed ID: 28285326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropeptide systems and new treatments for nicotine addiction.
    Bruijnzeel AW
    Psychopharmacology (Berl); 2017 May; 234(9-10):1419-1437. PubMed ID: 28028605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous cannabinoid and opioid systems and their role in nicotine addiction.
    Maldonado R; Berrendero F
    Curr Drug Targets; 2010 Apr; 11(4):440-9. PubMed ID: 20017727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroscience of nicotine for addiction medicine: novel targets for smoking cessation medications.
    D'Souza MS
    Prog Brain Res; 2016; 223():191-214. PubMed ID: 26806777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system.
    Berrendero F; Robledo P; Trigo JM; Martín-García E; Maldonado R
    Neurosci Biobehav Rev; 2010 Nov; 35(2):220-31. PubMed ID: 20170672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotine-specific and non-specific effects of cigarette smoking on endogenous opioid mechanisms.
    Nuechterlein EB; Ni L; Domino EF; Zubieta JK
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Aug; 69():69-77. PubMed ID: 27095017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mu Opioid Receptor Binding Correlates with Nicotine Dependence and Reward in Smokers.
    Kuwabara H; Heishman SJ; Brasic JR; Contoreggi C; Cascella N; Mackowick KM; Taylor R; Rousset O; Willis W; Huestis MA; Concheiro M; Wand G; Wong DF; Volkow ND
    PLoS One; 2014; 9(12):e113694. PubMed ID: 25493427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabotropic glutamate receptor 5 as a potential target for smoking cessation.
    Chiamulera C; Marzo CM; Balfour DJK
    Psychopharmacology (Berl); 2017 May; 234(9-10):1357-1370. PubMed ID: 27847973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational Research on Nicotine Dependence.
    Falcone M; Lee B; Lerman C; Blendy JA
    Curr Top Behav Neurosci; 2016; 28():121-50. PubMed ID: 26873019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the glutamatergic system in nicotine dependence : implications for the discovery and development of new pharmacological smoking cessation therapies.
    Liechti ME; Markou A
    CNS Drugs; 2008; 22(9):705-24. PubMed ID: 18698872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation.
    Li X; Semenova S; D'Souza MS; Stoker AK; Markou A
    Neuropharmacology; 2014 Jan; 76 Pt B(0 0):554-65. PubMed ID: 23752091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical role for the melanocortin 4 receptor in stress-induced relapse to nicotine seeking in rats.
    Qi X; Yamada H; Corrie LW; Ji Y; Bauzo RM; Alexander JC; Bruijnzeel AW
    Addict Biol; 2015 Mar; 20(2):324-35. PubMed ID: 24612112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of smoking with μ-opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects.
    Weerts EM; Wand GS; Kuwabara H; Xu X; Frost JJ; Wong DF; McCaul ME
    Addict Biol; 2014 Jul; 19(4):733-42. PubMed ID: 23252742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse.
    Jackson KJ; Carroll FI; Negus SS; Damaj MI
    Psychopharmacology (Berl); 2010 Jun; 210(2):285-94. PubMed ID: 20232057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell.
    Paterson NE; Balfour DJ; Markou A
    Eur J Neurosci; 2007 May; 25(10):3099-108. PubMed ID: 17561823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status.
    Buchhalter AR; Fant RV; Henningfield JE
    Drugs; 2008; 68(8):1067-88. PubMed ID: 18484799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of Peripheral κ-Opioid Receptors Normalizes Caffeine Effects Modified in Nicotine-Dependent Rats during Nicotine Withdrawal.
    Sudakov SK; Bogdanova NG
    Bull Exp Biol Med; 2016 Oct; 161(6):743-745. PubMed ID: 27785643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double target concept for smoking cessation.
    Wu J
    Acta Pharmacol Sin; 2010 Sep; 31(9):1015-8. PubMed ID: 20711220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The "stop" and "go" of nicotine dependence: role of GABA and glutamate.
    D'Souza MS; Markou A
    Cold Spring Harb Perspect Med; 2013 Jun; 3(6):. PubMed ID: 23732855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rate of nicotine metabolism and smoking cessation outcomes in a community-based sample of treatment-seeking smokers.
    Kaufmann A; Hitsman B; Goelz PM; Veluz-Wilkins A; Blazekovic S; Powers L; Leone FT; Gariti P; Tyndale RF; Schnoll RA
    Addict Behav; 2015 Dec; 51():93-9. PubMed ID: 26240944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.